CVRdatabase
Menu

AJ Vaccines A/S

Public limited companyCVR 37911143København SActive

AJ Vaccines A/S is a public limited company, based in København S, active in manufacture of pharmaceutical preparations, founded in 2016. The company made a loss in both 2024 and 2025, most recently DKK 483.4m. With 499 employees, the company is about 50 times larger than the industry median. Equity fell to DKK 288.5m in 2025.

Follow
PDF reportCompare

Key figures · financial year 2025

RevenueDKK 389.7m−5.6% vs. 2024
Net profit−DKK 483.4m+40.1% vs. 2024
EquityDKK 288.5m−42.5% vs. 2024
Employees499latest month from CVR

What has changed

calculated from recorded figures and dates

Financials: 2025 against 2024

  • Revenue fell 6% (2024 → 2025), to DKK 389.7m.
  • The loss got smaller: from DKK 807.1m to DKK 483.4m (2024 → 2025).
  • Equity fell 43% (2024 → 2025), to DKK 288.5m.

Employees

  • 25 fewer employees than a year earlier: 499 (07/2026) against 524 (07/2025).

Registrations, last 24 months

  • 21/05/2026: Share capital changed from 90,051,565 DKK to 106,564,072 DKK
  • 13/01/2026: Share capital changed from 73,633,747 DKK to 90,051,565 DKK
  • 08/10/2025: Share capital changed from 57,215,929 DKK to 73,633,747 DKK
  • 07/10/2025: Share capital changed from 46,790,614 DKK to 57,215,929 DKK
  • 03/10/2025: Share capital changed from 46,235,840 DKK to 46,790,614 DKK
  • 30/12/2024: Share capital changed from 43,645,768 DKK to 46,235,840 DKK

Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.

Financial statements

Financial years 2020–2025 · amounts in DKK thousand

Equity and net profit

−DKK 1bn−DKK 800m−DKK 600m−DKK 400m−DKK 200mDKK 0DKK 200mDKK 400mDKK 600mDKK 800mDKK 1bn202020212022202320242025
EquityNet profit
Financial figures for AJ Vaccines A/S
202020212022202320242025Change
Revenue351,618351,862420,982468,886412,969389,681−5.6%
Gross profit−313,896−303,976−65,971−30,723−587,049−220,277+62.5%
Operating profit (EBIT)−433,564−455,058−226,829−212,229−766,299−458,892+40.1%
Profit before tax−452,537−488,398−268,810−242,923−807,117−483,351+40.1%
Net profit−450,212−486,388−268,090−242,974−807,117−483,351+40.1%
Total assets1,727,6451,472,4661,534,0051,587,3371,088,929861,206−20.9%
Equity1,052,358815,875994,6631,020,362501,919288,465−42.5%
Liabilities675,287656,591539,343566,975587,010572,741−2.4%
Cash and cash equivalents20,69713,56478,3744,7728,4619,758+15.3%
Average number of employees702558556577581451−22.4%

Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report.

Download the figures as CSV · free with an account, amounts in whole DKK

−DKK 600m−DKK 500m−DKK 400m−DKK 300m−DKK 200m−DKK 100mDKK 0202020212022202320242025
Gross profitMedian, the industry (59 companies)

Signals from the financial statements

calculated from the 2025 figures

  • Loss for 6 years in a row

    Net result has been negative in 2020–2025.

    How is this calculated?

    Net result is negative in the two or more latest annual reports in a row.

  • Equity fell sharply

    Equity fell 43% from 2024 to 2025 (DKK 501.9m to DKK 288.5m).

    How is this calculated?

    Equity has fallen by at least 30% from the previous annual report, and it was positive the year before.

The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.

Annual reports

6 financial years
Annual reports for AJ Vaccines A/S
Financial yearPeriodPublishedFigures forDocuments
202501/01/2025 – 31/12/202514/07/2026The companyPDF not statedXBRL
202401/01/2024 – 31/12/202408/07/2025The companyPDFXBRL
202301/01/2023 – 31/12/202308/07/2024The companyPDFXBRL
202201/01/2022 – 31/12/202211/07/2023The companyPDFXBRL
202101/01/2021 – 31/12/202109/07/2022The companyPDFXBRL
202001/01/2020 – 31/12/202020/07/2021The companyPDFXBRL

The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.

Employees

monthly figures from CVR
010020030040050060008/2309/2310/2311/2312/2301/2402/2403/2404/2405/2406/2407/2408/2409/2410/2411/2412/2401/2502/2503/2504/2505/2506/2507/2508/2509/2510/2511/2512/2501/2602/2603/2604/2605/2606/2607/26
Employees

Position in the industry

59 companies in the database

Comparison with the other companies in manufacture of pharmaceutical preparations based on the latest financial year.

Gross profit−DKK 220.3mNo. 57 of 57
Better than 0% of the companies in the industry
EquityDKK 288.5mNo. 12 of 59
Better than 81% of the companies in the industry
Number of employees499No. 10 of 59
Better than 84% of the companies in the industry

Industry median: gross profit DKK 2.8m, net profit −DKK 2.2m, equity DKK 5.2m, 10 employees.

DKK 266kDKK 8.3mDKK 258mDKK 8bnDKK 79.6bn
Distribution of gross profit for 34 companies in the industry (latest financial year, logarithmic scale). Amber bar: where this company sits.

Compared with similar companies

size, age and company form
Rank among similar companies
GroupGross profitEquity
Companies with 200–499 employees796 companies in the comparison
No. 762of 763
Better than 0%
No. 200of 796
Better than 75%
Companies that are between 5 and 14 years old33,688 companies in the comparison
No. 33,586of 33,588
Better than 0%
No. 303of 33,687
Better than 99%
All companies of type A/S18,025 companies in the comparison
No. 17,780of 17,786
Better than 0%
No. 1,088of 18,024
Better than 94%

The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.

Compare with the industry

Manufacture of pharmaceutical preparations
Gross profit
  1. AJ Vaccines A/S−DKK 220.3m
  2. Novo Nordisk A/SDKK 250.3bn
  3. H. Lundbeck A/SDKK 20.4bn
Net profit
  1. AJ Vaccines A/S−DKK 483.4m
  2. Novo Nordisk A/SDKK 102.4bn
  3. H. Lundbeck A/SDKK 3.2bn
Equity
  1. AJ Vaccines A/SDKK 288.5m
  2. Novo Nordisk A/SDKK 194bn
  3. H. Lundbeck A/SDKK 24.9bn
Employees
  1. AJ Vaccines A/S499
  2. Novo Nordisk A/S27,279
  3. H. Lundbeck A/S2,261

Latest financial year per company. Choose up to three companies from the largest in the industry.

Owners and group

from the Public Ownership Register
Owners
  • AJ Vaccines Holding ApS100%
AJ Vaccines A/S

Management

6 active registrations

Executive management

Executive management at AJ Vaccines A/S
NameRoleAppointed
Ole VahlgrenCEO01/02/2022

Board of directors

Board of directors at AJ Vaccines A/S
NameRoleAppointed
Mustafa Nasir FarookiBoard member16/01/2017
Saddam Abdulqawi Hussein AlhumaikaniBoard member28/05/2020
Mohammed Ali A AlesayiBoard member24/03/2021
Abdulaziz Abdulhamid Abdulrhman AlbassamChair of the board28/08/2023
Tarek Sherif Ahmed Abbas HegazyBoard member23/07/2024
Founders
Accura Advokatpartnerselskab
Former management (22)
Former management at AJ Vaccines A/S
NameRoleAppointedResigned
Ivan MadsenChair of the board04/08/201610/08/2016
Poul Jagd MogensenBoard member04/08/201610/08/2016
Henrik Juul HansenCEO04/08/201610/08/2016
Henrik Juul HansenBoard member04/08/201610/08/2016
Helle Birk KrogsgaardChair of the board10/08/201616/01/2017
Mie Lund BuhlBoard member10/08/201616/01/2017
Pia Birgitte LadingDirector10/08/201616/01/2017
Pia Birgitte LadingBoard member10/08/201616/01/2017
Jesper Helmuth LarsenDirector16/01/201719/12/2018
Klaus HermansenCEO16/01/201720/12/2018
Klaus HermansenBoard member16/01/201720/12/2018
Tabassum KhanChair of the board16/01/201731/01/2022
Jesper Helmuth LarsenBoard member04/09/201828/05/2020
Saddam Abdulqawi Hussein AlhumaikaniBoard member04/09/201823/03/2020
Jesper Helmuth LarsenCEO20/12/201831/01/2022
Jerome Christian Roger CabannesDirector31/07/201901/02/2022
Jérome Christian Roger CabannesDirector31/07/201928/01/2021
Shan-E-Abbas AsharyBoard member28/05/202024/03/2021
Abdul Wahab Mohammed A AlesayiBoard member28/05/202024/03/2021
Abdulaziz Hamad AljomaihBoard member24/03/202131/01/2022
Shan-E-Abbas AsharyBoard member01/02/202223/07/2024
Abdulaziz Hamad AljomaihChair of the board01/02/202228/08/2023

Signing rule: Selskabet tegnes af tre bestyrelsesmedlemmer i forening eller af den samlede bestyrelse.

Address and production units

2 active production units

Artillerivej 5
2300 København S

København Municipality · Postcode 2300

Open in OpenStreetMap
Production units
Production unitAddressEmployeesP number
AJ Vaccines A/SArtillerivej 5, 2300 København S4291021638974
AJ Vaccines A/SAmagerfælledvej 106, 2300 København S701026868137

Purpose

Selskabets formål er at drive virksomhed med udvikling, produktion og handel til indenlandske og udenlandske kunder af vacciner og andre biologiske lægemidler samt anden virksomhed, der efter bestyrelsens skøn er forbundet dermed.

The purpose is quoted from the register in Danish.

Changes year by year

87 registered events
20263 changesaccounts 1 · capital 2
  • Annual report for 2025 published
  • Share capital changed from 90,051,565 DKK to 106,564,072 DKK
  • Share capital changed from 73,633,747 DKK to 90,051,565 DKK
20254 changescapital 3 · accounts 1
  • Share capital changed from 57,215,929 DKK to 73,633,747 DKK
  • Share capital changed from 46,790,614 DKK to 57,215,929 DKK
  • Share capital changed from 46,235,840 DKK to 46,790,614 DKK
  • Annual report for 2024 published
20244 changescapital 1 · management 2 · accounts 1
  • Share capital changed from 43,645,768 DKK to 46,235,840 DKK
  • Tarek Sherif Ahmed Abbas Hegazy appointed board member
  • Shan-E-Abbas Ashary stepped down as board member
  • Annual report for 2023 published
20235 changescapital 2 · management 2 · accounts 1
  • Share capital changed from 43,398,050 DKK to 43,645,768 DKK
  • Share capital changed from 41,228,206 DKK to 43,398,050 DKK
  • Abdulaziz Abdulhamid Abdulrhman Albassam appointed chair of the board
  • Abdulaziz Hamad Aljomaih stepped down as chair of the board
  • Annual report for 2022 published
202211 changescapital 3 · accounts 1 · management 7
  • Share capital changed from 40,812,869 DKK to 41,228,206 DKK
  • Share capital changed from 39,123,107 DKK to 40,812,869 DKK
  • Annual report for 2021 published
  • Share capital changed from 37,220,483 DKK to 39,123,107 DKK
  • Ole Vahlgren appointed ceo
  • Shan-E-Abbas Ashary appointed board member
  • Abdulaziz Hamad Aljomaih appointed chair of the board
  • Jerome Christian Roger Cabannes stepped down as director
  • Abdulaziz Hamad Aljomaih stepped down as board member
  • Jesper Helmuth Larsen stepped down as ceo
  • Tabassum Khan stepped down as chair of the board
20217 changescapital 1 · accounts 1 · management 5
  • Share capital changed from 34,987,230 DKK to 37,220,483 DKK
  • Annual report for 2020 published
  • Abdulaziz Hamad Aljomaih appointed board member
  • Mohammed Ali A Alesayi appointed board member
  • Abdul Wahab Mohammed A Alesayi stepped down as board member
  • Shan-E-Abbas Ashary stepped down as board member
  • Jérome Christian Roger Cabannes stepped down as director
20208 changescapital 3 · management 5
  • Share capital changed from 33,918,000 DKK to 34,987,230 DKK
  • Share capital changed from 32,325,000 DKK to 33,918,000 DKK
  • Abdul Wahab Mohammed A Alesayi appointed board member
  • Saddam Abdulqawi Hussein Alhumaikani appointed board member
  • Shan-E-Abbas Ashary appointed board member
  • Jesper Helmuth Larsen stepped down as board member
  • Saddam Abdulqawi Hussein Alhumaikani stepped down as board member
  • Share capital changed from 32,125,000 DKK to 32,325,000 DKK
20195 changescapital 3 · management 2
  • Share capital changed from 31,725,000 DKK to 32,125,000 DKK
  • Share capital changed from 30,750,000 DKK to 31,725,000 DKK
  • Jérome Christian Roger Cabannes appointed director
  • Jerome Christian Roger Cabannes appointed director
  • Share capital changed from 28,600,000 DKK to 30,750,000 DKK
20188 changescapital 2 · management 6
  • Share capital changed from 27,400,000 DKK to 28,600,000 DKK
  • Jesper Helmuth Larsen appointed ceo
  • Klaus Hermansen stepped down as board member
  • Klaus Hermansen stepped down as ceo
  • Jesper Helmuth Larsen stepped down as director
  • Saddam Abdulqawi Hussein Alhumaikani appointed board member
  • Jesper Helmuth Larsen appointed board member
  • Share capital changed from 26,000,000 DKK to 27,400,000 DKK
201713 changescapital 2 · management 9 · ownership 2
  • Share capital changed from 25,000,000 DKK to 26,000,000 DKK
  • Share capital changed from 500,001 DKK to 25,000,000 DKK
  • Klaus Hermansen appointed board member
  • Klaus Hermansen appointed ceo
  • Jesper Helmuth Larsen appointed director
  • Tabassum Khan appointed chair of the board
  • Mustafa Nasir Farooki appointed board member
  • Pia Birgitte Lading stepped down as board member
  • Pia Birgitte Lading stepped down as director
  • Mie Lund Buhl stepped down as board member
  • Helle Birk Krogsgaard stepped down as chair of the board
  • AJ Vaccines Holding ApS registered as owner (100%)
  • Statens Serum Institut is no longer registered as owner
201619 changesname 1 · address 1 · industry 1 · management 12 · ownership 3 · founded 1
  • Name changed from Aktieselskabet af august 2016 to AJ Vaccines A/S
  • Moved to Artillerivej 5, 2300 København S
  • Industry changed to Manufacture of pharmaceutical preparations (212000)
  • Pia Birgitte Lading appointed board member
  • Pia Birgitte Lading appointed director
  • Mie Lund Buhl appointed board member
  • Helle Birk Krogsgaard appointed chair of the board
  • Poul Jagd Mogensen stepped down as board member
  • Henrik Juul Hansen stepped down as board member
  • Ivan Madsen stepped down as chair of the board
  • Henrik Juul Hansen stepped down as ceo
  • Statens Serum Institut registered as owner (100%)
  • ACCURA ADVOKATPARTNERSELSKAB is no longer registered as owner
  • Registered as Aktieselskabet af august 2016
  • Poul Jagd Mogensen appointed board member
  • Henrik Juul Hansen appointed board member
  • Ivan Madsen appointed chair of the board
  • Henrik Juul Hansen appointed ceo
  • ACCURA ADVOKATPARTNERSELSKAB registered as owner (100%)

Related companies

Same industry in København

See all →

Same people in management

Largest in the industry

See all →

Source and updates

The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 23/10/2026.

View in CVRReport a correction